Nrf2 and/or its target gene might be involved in candidates of such genetic alteration, because Nrf2 is activated in many cancers and would favor cell growth arrest of cancers [53], [54] Thus, genetic experiments like ultra-deep sequencing will be needed in search of such alterations in both HPI cell and clinical HCC. This evidence concerns the gene NFE2L2 and cancer.